

## SUBSTANTIAL SHAREHOLDERS

### SUBSTANTIAL SHAREHOLDERS

So far as our Directors are aware, immediately following completion of the Global Offering, assuming the Over-allotment Option is not exercised and without taking into account any additional Shares which may be issued under the Share Incentivization Schemes, the Syracuse Holdback Shares and Juno Settlement Shares, the following persons will have interests and/or short positions in the Shares or underlying shares of our Company which would fall to be disclosed to us pursuant to the provisions of Divisions 2 and 3 of Part XV of the SFO, or, who is, directly or indirectly, interested in 10% or more of the nominal value of any class of share capital carrying rights to vote in all circumstances at general meetings of our Company or any other member of our Group. Our Directors are not aware of any arrangement which may at a subsequent date result in a change of control of our Company:

| Name of Substantial Shareholder                      | Capacity/Nature of Interest          | Total number of Shares/underlying shares as at the Latest Practicable Date | Approximate percentage of interest in our Company as at the Latest Practicable Date | Total number of Shares/underlying shares immediately after completion of the Global Offering | Approximate percentage of interest in our Company immediately after completion of the Global Offering |
|--|--------------------------------------|--|---|--|---|
| Juno <sup>(1)</sup>                                  | Beneficial interest                  | 74,896,670   | 26.89%  | 74,896,670   | 19.91%  |
| Celgene <sup>(1)</sup>                               | Interest in controlled corporation   | 74,896,670   | 26.89%  | 74,896,670   | 19.91%  |
| Bristol Myers Squibb <sup>(1)</sup>                  | Interest in controlled corporation   | 74,896,670   | 26.89%  | 74,896,670   | 19.91%  |
| Syracuse Cayman <sup>(2)</sup>                       | Beneficial interest                  | 48,513,377   | 17.42%  | 48,513,377   | 12.90%  |
| WXAT HK <sup>(3)</sup>                               | Beneficial interest                  | 38,232,570   | 13.73%  | 38,232,570   | 10.16%  |
| WXAT Shanghai <sup>(3)</sup>                         | Interest in controlled corporation   | 38,232,570   | 13.73%  | 38,232,570   | 10.16%  |
| WuXi AppTec <sup>(3)</sup>                           | Interest in controlled corporation   | 38,232,570   | 13.73%  | 38,232,570   | 10.16%  |
| TLS Beta Pte. Ltd. <sup>(4)</sup>                    | Beneficial interest                  | 22,668,740   | 8.14%   | 22,668,740   | 6.03%   |
| Temasek Life Sciences Private Limited <sup>(4)</sup> | Interest in a controlled corporation | 22,668,740   | 8.14%   | 22,668,740   | 6.03%   |
| Fullerton Management Pte Ltd <sup>(4)</sup>          | Interest in a controlled corporation | 22,668,740   | 8.14%   | 22,668,740   | 6.03%   |
| Temasek Holdings (Private) Limited <sup>(4)</sup>    | Interest in a controlled corporation | 22,668,740   | 8.14%   | 22,668,740   | 6.03%   |

## SUBSTANTIAL SHAREHOLDERS

| Name of Substantial Shareholder                    | Capacity/Nature of Interest   | Total number of Shares/underlying shares as at the Latest Practicable Date | Approximate percentage of interest in our Company as at the Latest Practicable Date | Total number of Shares/underlying shares immediately after completion of the Global Offering | Approximate percentage of interest in our Company immediately after completion of the Global Offering |
|--|---|--|---|--|---|
| Dr. Li <sup>(5)</sup>                              | Beneficial interest, interest in a controlled corporation, founder and trustee of discretionary trust | 21,795,080   | 7.83%   | 21,795,080   | 5.79%   |
| CJW Therapeutics Investment Limited <sup>(6)</sup> | Beneficial interest   | 19,552,250   | 7.02%   | 19,552,250   | 5.20%   |
| CPEChina Fund III, L.P. <sup>(6)</sup>             | Interest in a controlled corporation  | 19,552,250   | 7.02%   | 19,552,250   | 5.20%   |
| CPE Funds III Limited <sup>(6)</sup>               | Interest in a controlled corporation  | 19,552,250   | 7.02%   | 19,552,250   | 5.20%   |
| CPE Holdings Limited <sup>(6)</sup>                | Interest in a controlled corporation  | 19,552,250   | 7.02%   | 19,552,250   | 5.20%   |
| CPE Holdings International Limited <sup>(6)</sup>  | Interest in a controlled corporation  | 19,552,250   | 7.02%   | 19,552,250   | 5.20%   |

*Notes:*

- (1) As of the Latest Practicable Date, Juno directly held 70,231,140 Shares, consisting of 25,000,000 Shares, 6,419,750 Series A1 Preferred Shares, 33,168,250 Series A2 Preferred Shares, 4,665,530 Series X Preferred Shares and 977,610 Series B Preferred Shares (of which the Preferred Shares will be converted into Shares on a 1:1 basis by way of re-designation before Listing). Upon conversion of the Preferred Shares it holds, Juno will directly hold 70,231,140 Shares. Pursuant to the BCMA License Agreement, the 4,665,530 Juno Settlement Shares may be issued to Juno upon exercise of the second warrant as part of the second upfront payment. Juno is wholly-owned by Celgene which is in turn wholly-owned by Bristol Myers Squibb. As such, under the SFO, Bristol Myers Squibb (through its interest in a controlled corporation) is deemed to be interested in 74,896,670 Shares held by Juno.
- (2) As of the Latest Practicable Date, Syracuse Cayman directly held 43,380,910 Shares. Pursuant to the Asset Purchase Agreement, a maximum of 5,132,467 Syracuse Holdback Shares may be issued to Syracuse Cayman to settle US\$10.5 million for any future adjustments, without deductions including net working capital adjustment and taxes to be paid under the Asset Purchase Agreement. Syracuse Cayman is owned by approximately 150 individual and corporate entities and none of them is entitled to directly or indirectly control Syracuse Cayman in accordance with the SFO. As such, under the SFO, Syracuse Cayman is deemed to be interested in 48,513,377 Shares.

---

## SUBSTANTIAL SHAREHOLDERS

---

- (3) As of the Latest Practicable Date, WXAT HK directly held 38,232,570 Shares, consisting of 32,500,000 Shares, 2,166,670 Series A1 Preferred Shares, 2,099,480 Series A2 Preferred Shares and 1,466,420 Series B Preferred Shares (of which the Preferred Shares will be converted into Shares on a 1:1 basis by way of re-designation before Listing). WXAT HK is directly owned by WXAT Shanghai as to 80% and WuXi AppTec (Tianjin) Co., Ltd. as to 20%. WXAT Shanghai and WuXi AppTec (Tianjin) Co., Ltd. are directly wholly-owned by WuXi AppTec. As such, under the SFO, WXAT Shanghai and WuXi AppTec (through its interest in controlled corporations) are deemed to be interested in the 38,232,570 Shares held by WXAT HK.
- (4) As of the Latest Practicable Date, TLS Beta Pte. Ltd. directly held 22,668,740 Shares, consisting of 10,271,600 Series A1 Preferred Shares, 9,953,110 Series A2 Preferred Shares and 2,444,030 Series B Preferred Shares (of which the Preferred Shares will be converted into Shares on a 1:1 basis by way of re-designation before Listing). TLS Beta Pte. Ltd is a wholly-owned subsidiary of Temasek Life Sciences Private Limited, which is in turn a wholly-owned subsidiary of Fullerton Management Pte Ltd, which is in turn a wholly-owned subsidiary of Temasek Holdings (Private) Limited. As such, under the SFO, Temasek Life Sciences Private Limited, Fullerton Management Pte Ltd and Temasek Holdings (Private) Limited are each deemed to be interested in the 22,668,740 Shares held by TLS Beta Pte. Ltd.. The number of Shares immediately following the completion of the Global Offering has not taken into account Aranda Investments Pte. Ltd.'s subscription of Offer Shares pursuant to the relevant cornerstone investment agreement as further described under the section headed "Cornerstone Investors" in this prospectus.
- (5) As at the Latest Practicable Date, Dr. Li held (i) 1,500,000 Shares through his direct interests in JDI Capital Management Limited, (ii) 1,706,460 Shares consisting of 866,670 Series A1 Preferred Shares and 839,790 Series A2 Preferred Shares through his indirect interests in Park Place Capital Management & Consulting Limited and (iii) 6,000,000 Shares held by Dr. Li 2020 GRAT on trust for Dr. Li, with annuity payments to Dr. Li and with remainder interests, if any, to his family members, with Dr. Li as founder and trustee. Park Place Capital Management & Consulting Limited is wholly-owned by JDI Capital Management Limited which in turn is wholly-owned by Dr. Li. Dr. Li is also interested in 12,588,620 underlying Shares relating to the Restricted Share Units granted to him pursuant to the Restricted Share Unit Scheme. Accordingly, Dr. Li will be interested in aggregate 21,795,080 Shares.
- (6) As of the Latest Practicable Date, CJW Therapeutics Investment Limited directly held 19,552,250 Shares, consisting of 19,552,250 Series B Preferred Shares (of which the Preferred Shares will be converted into Shares on a 1:1 basis by way of re-designation before Listing). CJW Therapeutics Investment Limited is directly owned by CPEChina Fund III, L.P. ("**CPE Fund III**") as to 85% and CPE GLOBAL OPPORTUNITIES FUND, L.P. as to 15%. The general partner of CPE Fund III is CPE Funds III Limited which is wholly-owned by CPE Holdings Limited. CPE Holdings Limited is wholly-owned by CPE Holdings International Limited. CPE Holdings International Limited is owned by a number of shareholders that are natural persons, each holding less than 10% in CPE Holdings International Limited. As such, under the SFO, CPE Fund III, CPE Funds III Limited, CPE Holdings Limited and CPE Holdings International Limited are deemed to be interested in the 19,552,250 Shares held by CJW Therapeutics Investment Limited.
- (7) Assuming all Preferred Shares are converted into Shares on a one to one basis.
- (8) Figures above as adjusted after Share Subdivision.